3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Head & Neck
2
Genitourinary
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Quality of Life
2
tislelizumab
1
surufatinib
1
regorafenib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
copper dotatate CU-64
1
Surveys and Questionnaires
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Patient Reported Outcome Measures
1
PM 01183
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Irinotecan
1
Immunotherapy
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Drug Therapy
1
Cyclophosphamide
1
Cryotherapy
1
Control Groups
1
Clinical Trials, Phase II as Topic
1
Biological Therapy
1
Betaine
1
Acupuncture Therapy
1
Acupressure
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
regorafenib
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled